ReviewNeoplasia (New York, N.Y.)2007
Effects of recombinant erythropoietin on breast cancer-initiating cells.
Review in Neoplasia (New York, N.Y.), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 68 citations in OpenAlex.
- Erythropoietin in tissue engineering and beyond: a multifunctional macromolecule with emerging roles in organoids, immune modulation, and cancer research.Frontiers in bioengineering and biotechnology · 2026Review
- Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer.Science advances · 2024Article
- Novel Anti-Cancer Stem Cell Compounds: A Comprehensive Review.Pharmaceutics · 2024Review
- Unlocking the Secrets of Cancer Stem Cells with γ-Secretase Inhibitors: A Novel Anticancer Strategy.Molecules (Basel, Switzerland) · 2021Review
- Notch Signaling in Vascular Endothelial Cells, Angiogenesis, and Tumor Progression: An Update and Prospective.Frontiers in cell and developmental biology · 2021Review
- Cancer Stem Cells,Cells · 2020Review
- Serum erythropoietin levels, breast cancer and breast cancer-initiating cells.Breast cancer research : BCR · 2019Article
- Recombinant human erythropoietin stimulates melanoma tumor growth through activation of initiation factor eIF4E.Oncotarget · 2017Article
- Association between FBP1 and hypoxia-related gene expression in clear cell renal cell carcinoma.Oncology letters · 2016Article
- Combination therapy of RY10-4 with the γ-secretase inhibitor DAPT shows promise in treating HER2-amplified breast cancer.Oncotarget · 2016Article
- NOTCH1 is a poor prognostic factor for breast cancer and is associated with breast cancer stem cells.OncoTargets and therapy · 2016Article
- Targeting the Notch signaling pathway in cancer therapeutics.Thoracic cancer · 2014Review
- Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal.The Journal of clinical investigation · 2014Article
- Autocrine/paracrine erythropoietin regulates migration and invasion potential and the stemness of human breast cancer cells.Cancer biology & therapy · 2014Article
- Regulation of angiogenesis via Notch signaling in breast cancer and cancer stem cells.Biochimica et biophysica acta · 2013Review
- Radiation-induced Notch signaling in breast cancer stem cells.International journal of radiation oncology, biology, physics · 2013Article
- Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells.Journal of hematology & oncology · 2013Article
- Article
- Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells.Cancer letters · 2011Article
- Role of Notch and its oncogenic signaling crosstalk in breast cancer.Biochimica et biophysica acta · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundCancer anemia causes fatigue and correlates with poor treatment outcome. Erythropoietin has been introduced in an attempt to correct these defects. However, five recent clinical trials reported a negative impact of erythropoietin on survival and/or tumor control, indicating that experimental evaluation of a possible direct effect of erythropoietin on cancer cells is required. Cancer recurrence is thought to rely on the proliferation of cancer initiating cells (CICs). In breast cancer, CICs can be identified by phenotypic markers and their fate is controlled by the Notch pathway.
methodsIn this study, we investigated the effect of erythropoietin on CICs in breast cancer cell lines. Levels of erythropoietin receptor (EpoR), CD24, CD44, Jagged-1 expression, and activation of Notch-1 were assessed by flow cytometry. Self-renewing capacity of CICs was investigated in sphere formation assays.
resultsEpoR expression was found on the surface of CICs. Recombinant human Epo (rhEpo) increased the numbers of CICs and self-renewing capacity in a Notch-dependent fashion by induction of Jagged-1. Inhibitors of the Notch pathway and PI3-kinase blocked both effects.
conclusionsErythropoietin functionally affects CICs directly. Our observation may explain the negative impact of recombinant Epo on local control and survival of cancer patients with EpoR-positive tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.